{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:53:03Z","timestamp":1782316383238,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prnil.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T04:49:46Z","timestamp":1762577386000},"page":"116-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Irreversible electroporation in focal therapy for prostate cancer: current status and future directions"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0339-457X","authenticated-orcid":false,"given":"Francisco O.","family":"Durazo-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-027X","authenticated-orcid":false,"given":"Roc\u00edo","family":"Rold\u00e1n-Testillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-2645","authenticated-orcid":false,"given":"Lara","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Pilar","family":"Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4018-9853","authenticated-orcid":false,"given":"Liam N.","family":"Mendez-Bisgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Arezki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Elkhatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Hevia-Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Perlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-1763","authenticated-orcid":false,"given":"Jean de la","family":"Rosette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-5650","authenticated-orcid":false,"given":"Bernardino","family":"Mi\u00f1ana-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Anidjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip D.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5171-808X","authenticated-orcid":false,"given":"Rafael","family":"Sanchez-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.prnil.2025.11.001_bib2","article-title":"Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions","author":"Roldan-Testillano","year":"2025","journal-title":"Prostate Int"},{"issue":"2","key":"10.1016\/j.prnil.2025.11.001_bib3","first-page":"147","article-title":"Irreversible electroporation: evolution of a laboratory technique in interventional oncology","volume":"20","author":"Deipolyi","year":"2014","journal-title":"Diagn Interv Radiol"},{"issue":"3","key":"10.1016\/j.prnil.2025.11.001_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/siuj6030038","article-title":"Focal therapy for PCa \u2014 the technique","volume":"6","author":"Rodriguez-Sanchez","year":"2025","journal-title":"Soc Int Urol J"},{"issue":"2","key":"10.1016\/j.prnil.2025.11.001_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5534\/wjmh.240012","article-title":"Irreversible electroporation for the focal treatment of prostate cancer: a systematic review","volume":"43","author":"Zhang","year":"2025","journal-title":"World J Mens Health"},{"issue":"6","key":"10.1016\/j.prnil.2025.11.001_bib6","doi-asserted-by":"crossref","first-page":"712.e1","DOI":"10.1016\/j.clgc.2023.04.013","article-title":"An update on focal therapy for prostate cancer","volume":"21","author":"Ayerra Perez","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2025-0011","article-title":"Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications","volume":"59","author":"Jacobs","year":"2025","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.prnil.2025.11.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioelechem.2021.107871","article-title":"Cell death due to electroporation\u2014a review","volume":"141","author":"Batista Napotnik","year":"2021","journal-title":"Bioelectrochemistry"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib9","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1038\/s41467-021-24132-6","article-title":"Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells","volume":"12","author":"Burbach","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.prnil.2025.11.001_bib10","first-page":"614","article-title":"Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation\u2014IRE-IMMUNO study","volume":"134","author":"Geboers","year":"2024","journal-title":"BJU Int"},{"issue":"22","key":"10.1016\/j.prnil.2025.11.001_bib15","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3390\/molecules25225406","article-title":"In vitro study of calcium microsecond electroporation of prostate adenocarcinoma cells","volume":"25","author":"Kie\u0142bik","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib11","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.1038\/s41598-024-60413-y","article-title":"Effects of bipolar irreversible electroporation with different pulse durations in a prostate cancer mouse model","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02656736.2021.1914873","article-title":"Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice","volume":"38","author":"Rojo","year":"2021","journal-title":"Int J Hyperther"},{"issue":"9","key":"10.1016\/j.prnil.2025.11.001_bib13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/pharmaceutics16091109","article-title":"Synergistic strategies in prostate cancer therapy: electrochemotherapy and electromagnetic hyperthermia","volume":"16","author":"Vizcarra-Ramos","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib16","doi-asserted-by":"crossref","first-page":"22336","DOI":"10.1038\/s41598-022-25258-3","article-title":"Effects of different applied voltages of irreversible electroporation on prostate cancer in a mouse model","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.prnil.2025.11.001_bib17","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3390\/cancers14204987","article-title":"High-frequency pulsed electric field ablation in beagle model for treatment of prostate cancer","volume":"14","author":"Jeong","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.prnil.2025.11.001_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/cancers16051067","article-title":"Electroporation in translational medicine: from veterinary experience to human oncology","volume":"16","author":"Spugnini","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.prnil.2025.11.001_bib19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bju.16669","article-title":"Refining partial gland ablation for localised prostate cancer: the FALCON project","volume":"135","author":"Rodriguez-Sanchez","year":"2025","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.prnil.2025.11.001_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging\u2013targeted and systematic prostate biopsy to prevent infectious complications: The PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.prnil.2025.11.001_bib22","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","article-title":"Transperineal versus transrectal magnetic resonance imaging\u2013targeted biopsies for prostate cancer diagnosis: Final results of the randomized PERFECT trial (CCAFU-PR1)","volume":"7","author":"Ploussard","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.prnil.2025.11.001_bib23","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/cancers16122178","article-title":"A description and safety overview of irreversible electroporation for prostate tissue ablation in intermediate-risk prostate cancer patients: Preliminary results from the PRESERVE trial","volume":"16","author":"George","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prnil.2025.11.001_bib24","series-title":"510(k) substantial equivalence determination: nanoknife generator (K242687)","year":"2024"},{"key":"10.1016\/j.prnil.2025.11.001_bib25","series-title":"510(k) substantial equivalence determination: Electroporation system (N3000) (K240376). Silver spring, MD: Center for devices and radiological health","year":"2024"},{"issue":"8","key":"10.1016\/j.prnil.2025.11.001_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamasurg.2022.2230","article-title":"Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: A nonrandomized controlled trial","volume":"157","author":"Wang","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.prnil.2025.11.001_bib27","doi-asserted-by":"crossref","first-page":"760003","DOI":"10.3389\/fonc.2021.760003","article-title":"A multicenter single-arm objective performance criteria trial to determine the efficacy and safety of high-frequency irreversible electroporation as primary treatment for localized prostate cancer: A study protocol","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.prnil.2025.11.001_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/curroncol32090476","article-title":"Focal therapy for localized prostate cancer: A case series with cost analysis","volume":"32","author":"Sandberg","year":"2025","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.11.001_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bju.16746","article-title":"Perioperative complications of focal therapy for prostate cancer: Results from the GeRmAn Nationwide inpatient Data (GRAND) study","volume":"136","author":"Pyrgidis","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.11.001_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-025-04766-x","article-title":"Medicolegal landscape of prostate cancer ablative therapy: A national legal database analysis of malpractice claims (1970\u20132024)","author":"Xiao","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.prnil.2025.11.001_bib31","article-title":"Irreversible electroporation for localized prostate cancer: Risk-stratified oncologic outcomes and functional preservation","author":"Xia","year":"2025","journal-title":"Prostate Int"},{"issue":"6","key":"10.1016\/j.prnil.2025.11.001_bib32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/UPJ.0000000000000666","article-title":"Targeted ablation using ultrasound-guided irreversible electroporation of index tumors (TARGET study): Prospective development study evaluating safety, patient-reported outcomes, and oncologic efficacy","volume":"11","author":"Fainberg","year":"2024","journal-title":"Urol Pract"},{"issue":"Suppl 4","key":"10.1016\/j.prnil.2025.11.001_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bju.15948","article-title":"Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer","volume":"131","author":"Geboers","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/JU.0000000000002970","article-title":"Focal therapy of prostate cancer index lesion with irreversible electroporation: A prospective study with a median follow-up of 3 years","volume":"209","author":"Mi\u00f1ana L\u00f3pez","year":"2023","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.prnil.2025.11.001_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bju.15946","article-title":"Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer","volume":"131","author":"Scheltema","year":"2023","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.prnil.2025.11.001_bib36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00270-024-03826-6","article-title":"Long-term oncologic outcomes of image-guided irreversible electroporation for localized prostate cancer","volume":"47","author":"Collettini","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"13","key":"10.1016\/j.prnil.2025.11.001_bib37","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/cancers17132084","article-title":"Oncological and functional outcomes of hemi-ablation versus focal ablation for localized prostate cancer using irreversible electroporation","volume":"17","author":"Suberville","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prnil.2025.11.001_bib38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41391-023-00783-y","article-title":"A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer","volume":"27","author":"Zhang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.prnil.2025.11.001_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamasurg.2022.7516","article-title":"Effect of focal vs extended irreversible electroporation for the ablation of localized low- or intermediate-risk prostate cancer on early oncological control: A randomized clinical trial","volume":"158","author":"Zhang","year":"2023","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.prnil.2025.11.001_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JU.0000000000003051","article-title":"A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low\u2013intermediate risk prostate cancer","volume":"209","author":"de la Rosette","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2025.11.001_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.20210472","article-title":"Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study","volume":"63","author":"Yaxley","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.prnil.2025.11.001_bib43","first-page":"27","article-title":"Focal irreversible electroporation for localized prostate cancer: oncological and safety outcomes using mpMRI and transperineal biopsy follow-up","volume":"15","author":"Gielchinsky","year":"2023","journal-title":"Res Rep Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prnil.2022.08.004","article-title":"Irreversible electroporation for prostate cancer using PSMA PET-CT","volume":"11","author":"Shin","year":"2023","journal-title":"Prostate Int"},{"issue":"4","key":"10.1016\/j.prnil.2025.11.001_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00345-020-03275-z","article-title":"Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)","volume":"39","author":"Blazevski","year":"2021","journal-title":"World J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.prnil.2025.11.001_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bju.15947","article-title":"Salvage irreversible electroporation for radio-recurrent prostate cancer: The prospective FIRE trial","volume":"131","author":"Blazevski","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bju.16720","article-title":"The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy","volume":"136","author":"Zhang","year":"2025","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.prnil.2025.11.001_bib48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5534\/wjmh.230097","article-title":"Personalized treatment strategy in \u201clow-risk prostate cancer active surveillance candidates\u201d using irreversible electroporation: Prospective evaluation of feasibility, morbidity, functional and oncological outcomes","volume":"42","author":"Popeneciu","year":"2024","journal-title":"World J Mens Health"},{"issue":"6","key":"10.1016\/j.prnil.2025.11.001_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5152\/tud.2023.23150","article-title":"One-year follow-up results of transperineal biopsy for patients undergoing irreversible electroporation treatment in localized prostate cancer","volume":"49","author":"Altan","year":"2023","journal-title":"Urol Res Pract"},{"issue":"1","key":"10.1016\/j.prnil.2025.11.001_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12894-024-01506-8","article-title":"Radiation therapy and irreversible electroporation for intermediate-risk prostate cancer (RTIRE)","volume":"24","author":"Diven","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.prnil.2025.11.001_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euros.2023.03.003","article-title":"Prostate Cancer IRE Study (PRIS): A randomized controlled trial comparing focal therapy to radical treatment in localized prostate cancer","volume":"51","author":"Lantz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.prnil.2025.11.001_bib51","series-title":"Partial prostate ablation versus radical treatment (PART) trial protocol. Version 3.0","author":"Bryant","year":"2024"},{"issue":"Suppl 4","key":"10.1016\/j.prnil.2025.11.001_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bju.16207","article-title":"Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy","volume":"133","author":"Geboers","year":"2024","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.prnil.2025.11.001_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4111\/icu.20240229","article-title":"Prostate cancer theragnostics biomarkers: an update","volume":"65","author":"Kumar","year":"2024","journal-title":"Investig Clin Urol"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:28:58Z","timestamp":1782314938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2287888225000935"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.11.001","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible electroporation in focal therapy for prostate cancer: current status and future directions","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}